Memorial Sloan-Kettering Joins Sigma-Aldrich’s RNAi Partnership Program
Sigma-Aldrich said this week that the Memorial Sloan-Kettering Cancer Center has joined the company’s RNAi Partnership Program.
The program was established in 2006 as part of Sigma-Aldrich’s bid to strengthen ties between the company and academic users of its RNAi and other functional genomics products, as well as boost the company's visibility in the RNAi space (see RNAi News, 4/27/2006).
Participants in the program will get early access to new Sigma-Aldrich technologies, and will have a dedicated support team to assist with products from the company's functional genomics product portfolio.
Other members of the RNAi Partnership Program include Rutgers University; the University of Medicine and Dentistry, New Jersey; the Wistar Institute; Tufts University; Washington University of Saint Louis; the Cleveland Clinic; the Harvard Stem Cell Institute; and Princeton University.
RXi Acquires Oral RNAi Drug Delivery Tech from UMMS
RXi Pharmaceuticals this week announced that it has acquired an exclusive, worldwide license from the University of Massachusetts Medical School to technology related to the oral delivery of RNAi therapeutics.
The technology was developed by UMMS researcher and RXi co-founder Michael Czech and UMMS researcher and RXi collaborator Gary Ostroff.
Specific terms of the license were not disclosed.
Under a deal signed in January 2007, RXi has a three-year option to license the rights to all unrestricted therapeutic RNAi technology developed at the institution (see RNAi News, 1/18/2007). That arrangement is set to expire at the beginning of 2010.